Head and Neck Squamous Cell Carcinoma CPG Mini Module - Identifying Pseudoprogression and Managing Disease Unresponsive to Immunotherapy

The SITC Cancer Immunotherapy Guidelines Webinars connect clinicians with leading experts in the field and provide education about the evidence- and consensus-based recommendations in the clinical practice guidelines. To complement the advanced live webinar series, three on-demand, mini modules will assist learners in applying lessons learned on specific topics within the use of immunotherapy in their own practices and locate additional resources to continue their education.   

This mini module begins with a case presentation on a patient with recurrent HNSCC in the oropharynx and lungs.  Panelists Dan P. Zandberg, MD - UPMC Hillman Cancer Center, Ezra Cohen, MD, FRCPSC, FASCO - UC of San Diego, and Andrew Sikora, MD, PhD - University of Texas MD Anderson Cancer Center use this case as a starting point to discuss the incidence of pseudoprogresson during immunotherapy of HNSCC.  Panelists' insights into risks and benefits of transitioning patients from immunotherapy to chemotherapy are also addressed.  The discussion concludes with practical advice on distinguishing between pseudoprogression and unresponsive tumors. 

Run time: Approximately 12 minutes

Target Audience 

Clinicians and advanced practice providers who treat cancer patients are the target audience, including community physicians, oncologists, emergency room physicians, disease specialists, registered nurses, nurse practitioners, pharmacists, physician assistants and radiologists. 

SITC Online Education Disclaimer 

A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. 

The Quick Education Modules are part of the Cancer Immunotherapy Clinical Practice Guidelines Advanced Webinar Series supported, in part, by grants from Amgen and Merck & Co., Inc. (as of 9/20/2021). 
 
The SITC Clinical Practice Guidelines are produced and funded solely by SITC. No outside funding is received for the development of the manuscripts.